53 patents currently held

15 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2028. from the record

Of the 15 now held by other companies, 6 were conveyed to Novartis AG in the filing they arrived in, and 9 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Jul 2028

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Recombinant Host Cell Engineered to Overexpress Helper Proteins US 10,865,416

The most cited patent in this portfolio, cited by 12 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.

Ends Apr 2035 · High confidence Also notable

Drug Delivery Device US D1,029,237

A family of 5 related applications built on the 2024 grant. Protection runs to 2039.

Ends May 2039 · High confidence Also notable

Cabozantinib Salts And Their Use As Anti-Cancer Agents US 10,206,916

The earliest of the three still in force, granted 2019 and renewed since. Its term ends first, in 2036.

Ends Mar 2036 · High confidence

Formerly held, still cited

Notable

Multi-Copy Gene Protein Expression System US 11,851,666

Granted 2023. Computed term ends 2038.

now held by Novartis Pharma AG

Ends Sep 2038 · High confidence

Also notable

Injection Device US D928,941

Granted 2021. Computed term ends 2036.

conveyed to Novartis AG

Ends Aug 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Mar 22, 2027
The maintenance fee for Method for the Production of Ceftobiprole Medocaril (US 9,139,597) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
1 fee due May 10, 2027
The maintenance fee for Quantification of Misfolded TNFR2:FC (US 9,182,410) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
1 fee due Jul 5, 2027
The maintenance fee for Pharmaceutical Composition Containing Crystalline Sorafenib Tosylate (US 9,227,938) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
1 fee due Aug 23, 2027
The maintenance fee for Crystalline Form of Rivaroxaban Dihydrate (US 9,266,868) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
1 fee due Sep 3, 2027
The maintenance fee for Pharmaceutical Composition Containing Rifaximin Alpha & Delta (US 10,576,065) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
1 fee due Oct 30, 2027
The maintenance fee for Multi-Component Crystals of an Orally Available Hif Prolyl Hydroxylase Inhibitor (US 11,970,450) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 48 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Drug Delivery Device	5 in force	to Aug 2040
Method for Producing a Recombinant Protein on a Manufacturing Scale	2 in force	to Nov 2029
Crystalline Forms of an Orally Available, Selective Kit and Pdgfr Kinase Inhibitor	1 in force	to Mar 2043
An Inhaler Device	1 in force	to Sep 2042
Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid	1 in force	to Jul 2041

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 10,752,930	Method for Producing a Recombinant Protein on a Manufacturing Scale held by Boehringer Ingelheim RCV GmbH & Co. KG In force Term ends Jul 10, 2028 · High confidence	In force	Term ends Jul 10, 2028	High confidence
US 8,252,946	Crystalline Forms of Tigecycline Hydrochloride In force Term ends Feb 25, 2029 · High confidence	In force	Term ends Feb 25, 2029	High confidence
US 9,683,252	Method for Producing a Recombinant Protein on a Manufacturing Scale held by Boehringer Ingelheim RCV GmbH & Co. KG and Sandoz AG In force Term ends Nov 14, 2029 · High confidence	In force	Term ends Nov 14, 2029	High confidence
US 8,475,838	Rapidly-dissolving pharmaceutical composition for inhibiting ovulation In force Term ends Feb 24, 2030 · High confidence	In force	Term ends Feb 24, 2030	High confidence
US 8,513,224	Crystalline Form C of Tigecycline Dihydrochloride and Methods for Its Preparation In force Term ends Jun 22, 2030 · High confidence	In force	Term ends Jun 22, 2030	High confidence
US 8,946,441	Polymorphs of an Active Pharmaceutical Ingredient In force Term ends Jun 24, 2031 · High confidence	In force	Term ends Jun 24, 2031	High confidence
US 9,139,597	Method for the Production of Ceftobiprole Medocaril In force Term ends May 2, 2032 · High confidence	In force	Term ends May 2, 2032	High confidence
US 9,266,868	Crystalline Form of Rivaroxaban Dihydrate In force Term ends May 2, 2032 · High confidence	In force	Term ends May 2, 2032	High confidence
US 9,745,588	Transcription Terminator Sequences held by Sandoz AG and Boehringer Ingelheim RCV GmbH & Co. KG In force Term ends Jun 1, 2032 · High confidence	In force	Term ends Jun 1, 2032	High confidence
US 9,458,146	Crystalline Sodium Salt of an HIV Integrase Inhibitor In force Term ends Jul 4, 2032 · High confidence	In force	Term ends Jul 4, 2032	High confidence

10 of 53 patents shown.

Pro members see all 53.

Pro members: see all 53 patents

Also on record, not counted in the 53: 15 patents in force now held by others · 101 patents ended · 15 applications pending · 105 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Sandoz AG